What It Takes to Defend Deceptive Placebo Use
What It Takes to Defend Deceptive Placebo Use
复制标题
DOI：
10.1353/ken.2011.0015
复制
发表时间：
2011-09-01
影响因子：
1.4
通讯作者：
Barnhill, Anne
中科院分区：
文献类型：
--
作者：
Barnhill, Anne
对欺骗性使用安慰剂的完全辩护必须解决这一道德异议：欺骗性安慰剂的使用侵犯了患者的自主权，因为在拟议治疗的安慰剂性质上欺骗患者会阻止她在知情的情况下同意治疗。不幸的是，这一反对意见并不总是得到认可，也不能与其他伦理问题明确区分开来。我认为几位写了关于安慰剂使用的生物伦理学家对这一反对意见做出了多好的回应，或回避了这一反对意见。我的结论是，欺骗性安慰剂使用的捍卫者应该效仿奥诺拉·奥尼尔，辩称欺骗性安慰剂使用符合知情同意。
A complete defense of deceptive placebo use must address this ethical objection: deceptive placebo use violates patient autonomy, because deceiving a patient about the placebo nature of a proposed treatment prevents her from giving informed consent to the treatment. Unfortunately, this objection isn't always recognized and clearly disambiguated from other ethical concerns. I consider how well several bioethicists who write about placebo use have responded to, or evaded, this objection. I conclude that defenders of deceptive placebo use should, following the lead of Onora O'Neill, argue that deceptive placebo use is compatible with informed consent.